India, April 15 -- Stereotaxis Inc. (STXS) on Wednesday said it has agreed to acquire Robocath, a venture-backed developer of robotic technologies for interventional cardiology and neurointerventions.
The transaction includes an upfront payment of $20 million and additional contingent payments of up to $25 million tied to regulatory and commercial milestones, including U.S. FDA clearance of Robocath's next-generation system. The consideration will be paid in cash or Stereotaxis common stock, at the company's discretion.
Robocath is expected to contribute approximately $2 million in annual revenue in the first year following the acquisition, with the deal projected to reach breakeven by the third year, supported by commercial and operation...